Market Place
Sourcing Support
Haunted: Teva’s $1.2 billion ‘pay-for-delay’ penalty; which companies will get hit next?
Teva Pharmaceutical Industries, Ltd., which acquired Cephalon in 2012, will make a total payment of
Pharma Chess: Strategies adopted in the United States to block generics
When a generic drug comes to the U.S.
market, sales of brand drugs crash. The drop is more than 80%
